Erythropoiesis after therapy with recombinant human erythropoietin: A dose-response study in anemic cancer surgery patients

Marco Braga, L. Gianotti, O. Gentilini, A. Vignali, L. Corizia, V. Di Carlo

Research output: Contribution to journalArticle

Abstract

Background and Objectives: Preoperative treatment with 600 U/kg of recombinant human erythropoietin (r-HuEPO) effectively increases erythropoiesis in cancer patients. The aim of this study was to evaluate the erythropoietic response after different doses of r-HuEPO in order to find the minimum effective dose. Materials and Methods: Twenty anemic sideropenic patients (hemoglobin ≤ 110 g/l; serum iron <600 μg/l) with cancer of the gastrointestinal tract were randomly allocated to two groups: the first (n = 10) received 400 U/kg of r-HuEPO divided in 4 doses (100 U/kg each, every 4 days); the second (n = 10) received 200 U/kg of r-HuEPO (50 U/kg each, every 4 days). Both groups were given intravenous iron gluconate (125 mg) every day for 15 days. Results: After treatment, the serum iron level significantly rose in both groups. The production of new red blood cells was 176.3 ± 90.8 ml in the 200 U/kg group and 268.4 ± 79.4 ml in the 400 U/kg group (p = 0.036). The increase of hemoglobin was significantly higher in the 400 U/kg group (22.3 ± 2.0 g/l) than in the 200 U/kg group (14.1 ± 2.7 g/l) (p = 0.017). Conclusion: The r-HuEPO dose of 400 U/kg appears significantly more effective than the 200 U/kg to stimulate erythropoiesis in anemic sideropenic cancer patients.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalVox Sanguinis
Volume76
Issue number1
DOIs
Publication statusPublished - Jan 1999

Fingerprint

Erythropoiesis
Erythropoietin
Iron
Neoplasms
Hemoglobins
Therapeutics
Gastrointestinal Neoplasms
Serum
Erythrocytes

ASJC Scopus subject areas

  • Hematology

Cite this

Erythropoiesis after therapy with recombinant human erythropoietin : A dose-response study in anemic cancer surgery patients. / Braga, Marco; Gianotti, L.; Gentilini, O.; Vignali, A.; Corizia, L.; Di Carlo, V.

In: Vox Sanguinis, Vol. 76, No. 1, 01.1999, p. 38-42.

Research output: Contribution to journalArticle

@article{982e15454f0b47ac9146e6ac8a321985,
title = "Erythropoiesis after therapy with recombinant human erythropoietin: A dose-response study in anemic cancer surgery patients",
abstract = "Background and Objectives: Preoperative treatment with 600 U/kg of recombinant human erythropoietin (r-HuEPO) effectively increases erythropoiesis in cancer patients. The aim of this study was to evaluate the erythropoietic response after different doses of r-HuEPO in order to find the minimum effective dose. Materials and Methods: Twenty anemic sideropenic patients (hemoglobin ≤ 110 g/l; serum iron <600 μg/l) with cancer of the gastrointestinal tract were randomly allocated to two groups: the first (n = 10) received 400 U/kg of r-HuEPO divided in 4 doses (100 U/kg each, every 4 days); the second (n = 10) received 200 U/kg of r-HuEPO (50 U/kg each, every 4 days). Both groups were given intravenous iron gluconate (125 mg) every day for 15 days. Results: After treatment, the serum iron level significantly rose in both groups. The production of new red blood cells was 176.3 ± 90.8 ml in the 200 U/kg group and 268.4 ± 79.4 ml in the 400 U/kg group (p = 0.036). The increase of hemoglobin was significantly higher in the 400 U/kg group (22.3 ± 2.0 g/l) than in the 200 U/kg group (14.1 ± 2.7 g/l) (p = 0.017). Conclusion: The r-HuEPO dose of 400 U/kg appears significantly more effective than the 200 U/kg to stimulate erythropoiesis in anemic sideropenic cancer patients.",
author = "Marco Braga and L. Gianotti and O. Gentilini and A. Vignali and L. Corizia and {Di Carlo}, V.",
year = "1999",
month = "1",
doi = "10.1159/000031017",
language = "English",
volume = "76",
pages = "38--42",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Erythropoiesis after therapy with recombinant human erythropoietin

T2 - A dose-response study in anemic cancer surgery patients

AU - Braga, Marco

AU - Gianotti, L.

AU - Gentilini, O.

AU - Vignali, A.

AU - Corizia, L.

AU - Di Carlo, V.

PY - 1999/1

Y1 - 1999/1

N2 - Background and Objectives: Preoperative treatment with 600 U/kg of recombinant human erythropoietin (r-HuEPO) effectively increases erythropoiesis in cancer patients. The aim of this study was to evaluate the erythropoietic response after different doses of r-HuEPO in order to find the minimum effective dose. Materials and Methods: Twenty anemic sideropenic patients (hemoglobin ≤ 110 g/l; serum iron <600 μg/l) with cancer of the gastrointestinal tract were randomly allocated to two groups: the first (n = 10) received 400 U/kg of r-HuEPO divided in 4 doses (100 U/kg each, every 4 days); the second (n = 10) received 200 U/kg of r-HuEPO (50 U/kg each, every 4 days). Both groups were given intravenous iron gluconate (125 mg) every day for 15 days. Results: After treatment, the serum iron level significantly rose in both groups. The production of new red blood cells was 176.3 ± 90.8 ml in the 200 U/kg group and 268.4 ± 79.4 ml in the 400 U/kg group (p = 0.036). The increase of hemoglobin was significantly higher in the 400 U/kg group (22.3 ± 2.0 g/l) than in the 200 U/kg group (14.1 ± 2.7 g/l) (p = 0.017). Conclusion: The r-HuEPO dose of 400 U/kg appears significantly more effective than the 200 U/kg to stimulate erythropoiesis in anemic sideropenic cancer patients.

AB - Background and Objectives: Preoperative treatment with 600 U/kg of recombinant human erythropoietin (r-HuEPO) effectively increases erythropoiesis in cancer patients. The aim of this study was to evaluate the erythropoietic response after different doses of r-HuEPO in order to find the minimum effective dose. Materials and Methods: Twenty anemic sideropenic patients (hemoglobin ≤ 110 g/l; serum iron <600 μg/l) with cancer of the gastrointestinal tract were randomly allocated to two groups: the first (n = 10) received 400 U/kg of r-HuEPO divided in 4 doses (100 U/kg each, every 4 days); the second (n = 10) received 200 U/kg of r-HuEPO (50 U/kg each, every 4 days). Both groups were given intravenous iron gluconate (125 mg) every day for 15 days. Results: After treatment, the serum iron level significantly rose in both groups. The production of new red blood cells was 176.3 ± 90.8 ml in the 200 U/kg group and 268.4 ± 79.4 ml in the 400 U/kg group (p = 0.036). The increase of hemoglobin was significantly higher in the 400 U/kg group (22.3 ± 2.0 g/l) than in the 200 U/kg group (14.1 ± 2.7 g/l) (p = 0.017). Conclusion: The r-HuEPO dose of 400 U/kg appears significantly more effective than the 200 U/kg to stimulate erythropoiesis in anemic sideropenic cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0032920122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032920122&partnerID=8YFLogxK

U2 - 10.1159/000031017

DO - 10.1159/000031017

M3 - Article

C2 - 9933852

AN - SCOPUS:0032920122

VL - 76

SP - 38

EP - 42

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 1

ER -